Get all premium features to the best stock analysis tool

New York, New York--(Newsfile Corp. - March 27, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) resulting from allegations that Aldeyra may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Aldeyra securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

New York, New York--(Newsfile Corp. - March 27, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Aldeyra Therapeutics, Inc. ("Aldeyra Therapeutics, Inc.") (NASDAQ: ALDX) concerning potential violations of the federal securities laws. Throughout 2024 and 2025, Aldeyra's made forward-looking statements regarding the development and regulatory prospects of reproxalap for the treatment of dry eye disease.

NEW YORK, March 26, 2026 /PRNewswire/ --  Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) resulting from allegations that Aldeyra may have issued materially misleading business information to the investing public. So What: If you purchased Aldeyra securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

NEW YORK, March 26, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Aldeyra Therapeutics, Inc. ("Aldeyra" or the "Company") (NASDAQ: ALDX).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

NEW YORK, March 25, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) resulting from allegations that Aldeyra may have issued materially misleading business information to the investing public.

Aldeyra Therapeutics Stock Falls After FDA Issues Complete Response Letter Rejecting Reproxalap for Dry Eye Disease NEW YORK, March 25, 2026 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) shares dropped approximately 70% after the FDA issued a Complete Response Letter for reproxalap, the Company's dry-eye therapy candidate, citing insufficient efficacy. Shareholders who lost money on their ALDX investment are encouraged to submit their information here.

NEW YORK, March 24, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Aldeyra Therapeutics, Inc. (“Aldeyra” or the “Company”) (NASDAQ: ALDX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.